Business Context and Reporting Period
This Form 8-K is filed by TRxADE Health, Inc. (noting a discrepancy with the request metadata which listed "Scienture Holdings, Inc.") for the reporting period ending June 23, 2023. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol MEDS.
Key Financial Metrics
This filing is a current report regarding corporate governance and listing status; it does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only quantitative data disclosed relates to share counts:
- Publicly Held Shares: Approximately 310,057 (post-split basis as of June 22, 2023).
- Nasdaq Minimum Requirement: 500,000 publicly held shares.
Material Changes and Corporate Actions
Item 3.01: Notice of Delisting
On June 23, 2023, Nasdaq notified the Company of non-compliance with Listing Rule 5550(a)(4) due to insufficient publicly held shares. The Company has until August 7, 2023, to submit a plan to regain compliance. Failure to secure an accepted plan may lead to an appeal before a Nasdaq Hearings Panel.
Item 5.03: Amendments to Articles of Incorporation
On June 26, 2023, the Company filed a Certificate of Designation for Series B Preferred Stock with the Delaware Secretary of State. Key terms include:
- Dividends/Voting: Non-participating, no dividends, no voting rights, no redemption rights.
- Conversion: Automatically converts into 100 shares of common stock upon stockholder approval.
- Repurchase Trigger: If a merger or acquisition with Superlatus, Inc. does not close by December 31, 2023, the Company must repurchase all Series B Preferred Stock at the original purchase price.
Guidance, Outlook, and Risks
The filing does not contain financial guidance or management commentary on future performance. The primary risks identified are:
- Delisting Risk: Potential removal from Nasdaq if the Company fails to submit an acceptable compliance plan by August 7, 2023, or fails to regain compliance thereafter.
- Transaction Risk: The obligation to repurchase Series B Preferred Stock if the Superlatus, Inc. transaction is not completed by year-end 2023.
Investor Verification Checklist
- Verify the Company's plan to regain Nasdaq compliance (deadline: August 7, 2023).
- Confirm the status of the proposed merger/acquisition with Superlatus, Inc. and the likelihood of closing before December 31, 2023.
- Review the full text of the Certificate of Designation for Series B Preferred Stock (Exhibit 3.1) for any additional covenants.
- Monitor subsequent filings for updates on the publicly held share count.